With this approval, leqembi iqlik is the first monoclonal antibody that clears amyloid beta for the treatment of early alzheimer’s disease that is approved for subcutaneous administration using an autoinjector. Fda approves leqembi's subcutaneous formulation, enhancing accessibility for alzheimer treatment and paving the way for future combination therapies. Leqembi iqlik will be launched on october 6, 2025 in the u.s
Leqembi is the second of a new category of medications approved for alzheimer’s disease that target the fundamental pathophysiology of the disease Fda approval was supported by phase 3 clarity ad extension trial data, showing that switching to the weekly leqembi iqlik autoinjector after 18 months of iv dosing maintains clinical and. These medications represent an important advancement in the ongoing fight to effectively treat alzheimer’s disease.
